Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

When short-sellers (bears) bet heavily against companies on the S&P 500 (IVV), investors should not ignore them. Enphase ...

But its financial fortunes have reversed since then due to declining demand for COVID-19 shots and slow uptake for an RSV vaccine it’s also brought to market. Moderna has revised its revenue guidance ...

Moderna Inc. (NASDAQ: MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable. 1 Over one-third of adults aged 18-59 years ...

Despite questions coming from federal changes, Colorado’s chief medical officer says he thinks “there will be enough vaccines ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...